Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
How to Pre-Load Assassin's Creed Mirage
How Much is My Fortnite Account Worth in 2023?
Clippy 2.0: How Microsoft's new AI assistant will make your life easier
Olivia Dunne: 5 untold secrets about TikTok sensation and 'SI Swim' star
Nintendo Switch 2 'will be similar to PlayStation 4'
Google's Bard AI chatbot is vulnerable to use by hackers. So is ChatGPT.
Andrew Tate: Parents and teachers concerned over misogynistic influencer's 'damaging and toxic' content
Roku Indoor Camera 360° SE Review